首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1915212

全球藥物發現技術市場（按產品、技術、製程和治療領域分類）－預測至2030年

Drug Discovery Technologies Market by Product, Technology, Process, Therapeutic Area - Global Forecast to 2030

出版日期: 2026年01月15日 | 出版商:

MarketsandMarkets | 英文 489 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球藥物研發技術市場預計將從2025年的305.8億美元成長到2030年的515.1億美元，預測期內複合年成長率（CAGR）為11.0%。市場成長的主要驅動力是先進篩檢平台的日益普及以及向3D細胞培養、類器官和晶片器官模型的轉變。

調查範圍
調查期	2024-2030
基準年	2024
預測期	2025-2030
單元	10億美元
部分	產品、技術、工藝、治療領域、最終用戶
目標區域	北美、歐洲、亞太地區、拉丁美洲、中東和非洲

這些技術增強了疾病相關性，提高了預測準確性，並支援高效可靠的藥物研發流程。此外，標靶治療和精準醫療的興起進一步推動了市場需求。然而，高昂的技術成本、複雜的工作流程以及對專業技術人員的需求仍然限制著市場成長。

預計在預測期內，基於In Silico/人工智慧的藥物發現領域將以最高的複合年成長率成長。

在藥物研發技術市場中，基於In Silico/人工智慧的藥物發現技術細分市場正以最高的複合年成長率成長，這主要得益於其能夠縮短藥物研發週期、降低成本並提高成功率。這些技術利用計算建模、機器學習和資料分析來快速識別和最佳化候選藥物。透過分析大規模生物和化學資料集，基於人工智慧的平台能夠在早期階段實現精準的標靶識別、先導化合物篩檢和毒性預測。這減少了對試驗的實驗室方法的依賴，並最大限度地降低了後期研發失敗的風險。其可擴充性、速度以及對精準醫療的支援能力，使得In Silico/人工智慧的技術成為製藥和生物技術公司不可或缺的工具，從而推動了其在市場上的廣泛應用。

腫瘤治療領域佔據了最大的市場。

腫瘤領域佔據了最大的市場。這一成長主要得益於全球癌症發病率的不斷上升以及對標靶治療和個人化治療研發的日益重視。先進的篩檢平台、高通量檢測和細胞模型被廣泛用於識別潛在候選藥物、驗證標靶和最佳化先導化合物。對癌症檢驗的積極投入、不斷拓展的臨床研發管線以及製藥公司與研究機構之間日益密切的合作，進一步推動了這些技術的應用。藥物研發效率的提高以及對更有效癌症治療方法的需求，持續推動全球腫瘤領域的成長。

預計在預測期內，美國將以最高的複合年成長率成長。

由於多種因素，美國藥物研發技術市場正經歷最快的成長。大型製藥和生物技術公司的強大實力、先進的研究基礎設施以及大量正在進行的腫瘤學計畫是關鍵促進因素。高通量篩檢、3D細胞模型和晶片器官平台在癌症研究中的日益普及推動了市場需求。支持性的監管政策、大量的公共和私人生物醫學研究資金以及對精準醫療的重視進一步促進了市場擴張。先進藥物研發技術的廣泛應用以及產業界和研究機構之間的密切合作促進了創新，並確保了高品質的研究成果，從而鞏固了北美在全球的主導地位。

本報告分析了全球藥物發現技術市場，深入探討了關鍵促進因素和限制因素、產品開發和創新以及競爭格局。

波特五力分析
宏觀經濟展望
- GDP趨勢與預測
- 醫療產業的全球趨勢
- 全球製藥業研究趨勢
價值鏈分析
生態系分析
定價分析
- 主要企業最終用戶平均售價（2024 年）
- 主要企業產品平均售價趨勢（2022-2024）
- 依技術分類的平均售價趨勢（2022-2024）
- 各地區平均售價趨勢（2022-2024）
貿易分析
- HS編碼3822.00的進口方案
- HS編碼3822.00的出口場景
- HS編碼9027.00的進口方案
- HS編碼9027.00的出口場景
重大會議和活動（2025-2026）
影響客戶業務的趨勢/顛覆性因素
投資和資金籌措方案
案例研究分析
2025年美國關稅對藥物研發技術市場的影響
- 主要關稅稅率
- 價格影響分析
- 對各國/地區的主要影響
- 對終端用戶產業的影響

第6章：技術進步、人工智慧影響、專利、創新與未來應用

主要新技術
- 高通量篩檢(HTS) 與自動化
- 自動化液體處理
鄰近技術
- In Silico藥物發現平台
- 藥物發現資訊實驗室的數位化
技術/產品藍圖
專利分析
- 調查方法
- 專利申請數量
- 主要專利列表
未來應用
人工智慧/生成式人工智慧對藥物發現技術市場的影響
- 主要應用案例和市場潛力
- 人工智慧驅動藥物發現工作流程的最佳實踐
- 人工智慧在藥物研發技術市場的案例研究
- 相互關聯的相鄰生態系及其對市場參與者的影響
- 客戶對在藥物發現技術市場中採用生成式分子設計的準備情況

第7章永續性與監管環境

地方法規和合規性
- 監管機構、政府機構和其他組織
- 業界標準
對永續性的承諾
永續性影響和監管政策舉措
認證、標籤和環境標準

第8章：顧客狀況與購買行為

決策流程
買方相關利益者和採購評估標準
- 採購過程中的關鍵相關利益者
- 主要採購標準：最終用戶
招募障礙和內部挑戰
來自各個終端使用者產業的未滿足需求

第9章藥物發現技術市場（依產品分類）

試劑和耗材
裝置
生物資訊學工具和軟體

第10章依技術分類的藥物發現技術市場

高通量篩檢（HTS）技術
次世代定序
聚合酵素鏈鎖反應
In Silico/人工智慧的藥物發現技術
X光晶體結構分析
層析法
質譜分析
其他技術

第11章按流程分類的藥物發現技術市場

目標識別
目標檢驗
命中線索識別
先導藥物最適化
候選人檢驗

第12章按治療領域分類的藥物發現技術市場

腫瘤學
感染疾病
心血管疾病
神經系統疾病
內分泌和代謝紊亂
自體免疫疾病
其他治療領域

第13章依最終用戶分類的藥物發現技術市場

製藥和生物技術公司
學術研究機構
委外研發機構（CRO）

第14章區域藥物發現技術市場

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 墨西哥
- 其他拉丁美洲
中東
- 海灣合作理事會國家
- 其他中東地區
非洲

第15章競爭格局

概述
主要企業的競爭策略/優勢
收入分析
市佔率分析
品牌/產品對比
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGAA
- AGILENT TECHNOLOGIES, INC.
- REVVITY
- ILLUMINA, INC.
企業評估矩陣：主要企業（2024）
公司評估矩陣：Start-Ups/中小企業（2024 年）
公司估值和財務指標
競爭場景

第16章：公司簡介

主要企業
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGAA
- AGILENT TECHNOLOGIES, INC.
- REVVITY
- ILLUMINA, INC.
- DANAHER CORPORATION
- F. HOFFMANN-LA ROCHE LTD
- BRUKER
- QIAGEN
- BIO-RAD LABORATORIES, INC.
- TECAN TRADING AG
- TAKARA BIO INC.
- CORNING INCORPORATED
- HAMILTON COMPANY
- PACBIO
- OXFORD NANOPORE TECHNOLOGIES PLC
- PROMEGA CORPORATION
- WATERS CORPORATION
- SARTORIUS AG
- BD
- EPPENDORF SE
- SHIMADZU CORPORATION
- AURORA BIOMED INC.
- STANDARD BIOTOOLS
- JEOL LTD.
- GILSON INCORPORATED
- BIOMERIEUX
- GREINER AG
- BGI GROUP
- PORVAIR
其他公司
- POLARIS GENOMICS
- BICO
- CREATIVE BIOARRAY
- SPHERE BIO
- GENSCRIPT
- SCHRODINGER, INC.
- LECO CORPORATION
- TRANSGEN BIOTECH CO., LTD
- BMG LABTECH
- NANOTEMPER TECHNOLOGIES
- MGI TECH CO., LTD.
- ARACELI BIOSCIENCES
- ANALYTIK JENA GMBH+CO. KG
- BIOSOLVEIT GMBH
- EVOSEP

第17章調查方法

第18章附錄

簡介目錄圖表

Product Code: BT 9820

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2025-2030
Units Considered	Value (USD billion)
Segments	Product, Technology, Process, Therapeutic Area, End User
Regions covered	North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

Drug Discovery Technologies Market - IMG1

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.

The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America's leading position globally.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side - 70% and Demand Side- 30%
By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMERIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT
3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%)

4 MARKET OVERVIEW

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
  - 4.2.1.1 Increasing adoption of advanced screening platforms
  - 4.2.1.2 Shift toward biologics and advanced therapeutic modalities
  - 4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional models
  - 4.2.1.4 Technological innovations in assay miniaturization and automation
- 4.2.2 RESTRAINTS
  - 4.2.2.1 High up-front investment in instruments, automation, and data infrastructure
  - 4.2.2.2 Shortage of skilled personnel
- 4.2.3 OPPORTUNITIES
  - 4.2.3.1 Growing demand for in-silico-based discovery
  - 4.2.3.2 Increasing need for specialized ADME/Toxicology testing
- 4.2.4 CHALLENGES
  - 4.2.4.1 Assay reproducibility and standardization issues
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 BARGAINING POWER OF BUYERS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
- 5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024
- 5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  - 5.5.2.1 Average selling price of instruments, by key player, 2024
  - 5.5.2.2 Average selling price of consumables, by key player, 2024
- 5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022-2024
- 5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
5.6 TRADE ANALYSIS
- 5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00
- 5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00
- 5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00
- 5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00
5.7 KEY CONFERENCES AND EVENTS, 2025-2026
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT AND FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
- 5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT
- 5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY
- 5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN
5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 KEY IMPACT ON COUNTRIES/REGIONS
  - 5.11.4.1 US
  - 5.11.4.2 Europe
  - 5.11.4.3 Asia Pacific
- 5.11.5 END-USE INDUSTRY IMPACT
  - 5.11.5.1 Pharmaceutical and Biotechnology Companies
  - 5.11.5.2 Academic and Research Institutes
  - 5.11.5.3 Contract Research Organizations (CROs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION
- 6.1.2 AUTOMATED LIQUID HANDLING
6.2 ADJACENT TECHNOLOGIES
- 6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS
- 6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION
6.3 TECHNOLOGY/PRODUCT ROADMAP
6.4 PATENT ANALYSIS
- 6.4.1 METHODOLOGY
- 6.4.2 NUMBER OF PATENTS FILED
- 6.4.3 LIST OF KEY PATENTS
6.5 FUTURE APPLICATIONS
6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET
- 6.6.1 TOP USE CASES AND MARKET POTENTIAL
- 6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS
- 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET
- 6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
- 6.6.5 CLIENTS' READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
  - 7.1.2.1 North America
    - 7.1.2.1.1 US
    - 7.1.2.1.2 Canada
  - 7.1.2.2 Europe
    - 7.1.2.2.1 UK
  - 7.1.2.3 Asia Pacific
    - 7.1.2.3.1 China
    - 7.1.2.3.2 Japan
    - 7.1.2.3.3 India
    - 7.1.2.3.4 South Korea
    - 7.1.2.3.5 Australia
    - 7.1.2.3.6 Rest of Asia Pacific
7.2 SUSTAINABILITY INITIATIVES
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR

8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT

9.1 INTRODUCTION
9.2 REAGENTS & CONSUMABLES
- 9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH
9.3 INSTRUMENTS
- 9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET
9.4 BIOINFORMATICS TOOLS & SOFTWARE
- 9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET

10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY

10.1 INTRODUCTION
10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES
- 10.2.1 AUTOMATED LIQUID HANDLING
  - 10.2.1.1 Increasing focus on precision, integration, and productivity to drive market
- 10.2.2 MICROPLATE-BASED HTS
  - 10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D to fuel market
- 10.2.3 LAB-ON-A CHIP
  - 10.2.3.1 Increasing demand for more predictive preclinical models to boost market
- 10.2.4 LABEL-FREE TECHNOLOGY
  - 10.2.4.1 Real-time, label-free interaction to accelerate segment growth
10.3 NEXT-GENERATION SEQUENCING
- 10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET
10.4 POLYMERASE CHAIN REACTION
- 10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET
10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES
- 10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET
10.6 X-RAY CRYSTALLOGRAPHY
- 10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET
10.7 CHROMATOGRAPHY
- 10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH
10.8 MASS SPECTROMETRY
- 10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET
10.9 OTHER TECHNOLOGIES

11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS

11.1 INTRODUCTION
11.2 TARGET IDENTIFICATION
- 11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET
11.3 TARGET VALIDATION
- 11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH
11.4 HIT-TO-LEAD IDENTIFICATION
- 11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET
11.5 LEAD OPTIMIZATION
- 11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET
11.6 CANDIDATE VALIDATION
- 11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH

12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA

12.1 INTRODUCTION
12.2 ONCOLOGY
- 12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH
12.3 INFECTIOUS DISEASES
- 12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET
12.4 CARDIOVASCULAR DISEASES
- 12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET
12.5 NEUROLOGICAL DISEASES
- 12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET
12.6 ENDOCRINE & METABOLIC DISORDERS
- 12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET
12.7 AUTOIMMUNE DISORDERS
- 12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET
12.8 OTHER THERAPEUTIC AREAS

13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER

13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH
13.3 ACADEMIC & RESEARCH INSTITUTES
- 13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC-INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH
13.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
- 13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH

14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION

14.1 INTRODUCTION
14.2 NORTH AMERICA
- 14.2.1 US
  - 14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth
- 14.2.2 CANADA
  - 14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth
14.3 EUROPE
- 14.3.1 GERMANY
  - 14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market
- 14.3.2 UK
  - 14.3.2.1 Increasing focus on next-generation computational platforms to promote growth
- 14.3.3 FRANCE
  - 14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market
- 14.3.4 ITALY
  - 14.3.4.1 Rising research funding to contribute to growth
- 14.3.5 SPAIN
  - 14.3.5.1 Well-established network of research centers and universities to boost market
- 14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
- 14.4.1 CHINA
  - 14.4.1.1 Global partnerships to propel market
- 14.4.2 JAPAN
  - 14.4.2.1 Rising integration of AI and international partnerships to favor growth
- 14.4.3 INDIA
  - 14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth
- 14.4.4 AUSTRALIA
  - 14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth
- 14.4.5 SOUTH KOREA
  - 14.4.5.1 Favorable public policies to support growth
- 14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
- 14.5.1 BRAZIL
  - 14.5.1.1 Public-private collaborations to bolster growth
- 14.5.2 MEXICO
  - 14.5.2.1 Rising demand for AI-powered research to support growth
- 14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST
- 14.6.1 GCC COUNTRIES
  - 14.6.1.1 Saudi Arabia
    - 14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market
  - 14.6.1.2 UAE
    - 14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth
  - 14.6.1.3 Rest of GCC countries
- 14.6.2 REST OF MIDDLE EAST
14.7 AFRICA
- 14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET

15 COMPETITIVE LANDSCAPE

15.1 OVERVIEW
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
15.3 REVENUE ANALYSIS
15.4 MARKET SHARE ANALYSIS
15.5 BRAND/PRODUCT COMPARISON
- 15.5.1 THERMO FISHER SCIENTIFIC INC.
- 15.5.2 MERCK KGAA
- 15.5.3 AGILENT TECHNOLOGIES, INC.
- 15.5.4 REVVITY
- 15.5.5 ILLUMINA, INC.
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 15.6.1 STARS
- 15.6.2 EMERGING LEADERS
- 15.6.3 PERVASIVE PLAYERS
- 15.6.4 PARTICIPANTS
- 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 15.6.5.1 Company footprint
  - 15.6.5.2 Region footprint
  - 15.6.5.3 Product footprint
  - 15.6.5.4 Technology footprint
  - 15.6.5.5 Process footprint
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 15.7.1 PROGRESSIVE COMPANIES
- 15.7.2 RESPONSIVE COMPANIES
- 15.7.3 DYNAMIC COMPANIES
- 15.7.4 STARTING BLOCKS
- 15.7.5 COMPETITIVE BENCHMARKING
  - 15.7.5.1 Detailed list of key startups/SMEs
  - 15.7.5.2 Competitive benchmarking of key startups/SMEs
15.8 COMPANY VALUATION AND FINANCIAL METRICS
15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
- 15.9.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

16.1 KEY PLAYERS
- 16.1.1 THERMO FISHER SCIENTIFIC INC.
  - 16.1.1.1 Business overview
  - 16.1.1.2 Products offered
  - 16.1.1.3 Recent developments
    - 16.1.1.3.1 Product launches
    - 16.1.1.3.2 Deals
    - 16.1.1.3.3 Expansions
  - 16.1.1.4 MnM view
    - 16.1.1.4.1 Key strengths/Right to win
    - 16.1.1.4.2 Strategic choices
    - 16.1.1.4.3 Weaknesses/Competitive threats
- 16.1.2 MERCK KGAA
  - 16.1.2.1 Business overview
  - 16.1.2.2 Products offered
  - 16.1.2.3 Recent developments
    - 16.1.2.3.1 Deals
    - 16.1.2.3.2 Expansions
  - 16.1.2.4 MnM view
    - 16.1.2.4.1 Key strengths/Right to win
    - 16.1.2.4.2 Strategic choices
    - 16.1.2.4.3 Weaknesses/Competitive threats
- 16.1.3 AGILENT TECHNOLOGIES, INC.
  - 16.1.3.1 Business overview
  - 16.1.3.2 Products offered
  - 16.1.3.3 Recent developments
    - 16.1.3.3.1 Product launches
    - 16.1.3.3.2 Expansions
  - 16.1.3.4 MnM view
    - 16.1.3.4.1 Key strengths/Right to win
    - 16.1.3.4.2 Strategic choices
    - 16.1.3.4.3 Weaknesses/Competitive threats
- 16.1.4 REVVITY
  - 16.1.4.1 Business overview
  - 16.1.4.2 Products offered
  - 16.1.4.3 Recent developments
    - 16.1.4.3.1 Product launches
    - 16.1.4.3.2 Deals
    - 16.1.4.3.3 Expansions
  - 16.1.4.4 MnM view
    - 16.1.4.4.1 Key strengths/Right to win
    - 16.1.4.4.2 Strategic choices
    - 16.1.4.4.3 Weaknesses/Competitive threats
- 16.1.5 ILLUMINA, INC.
  - 16.1.5.1 Business overview
  - 16.1.5.2 Products offered
  - 16.1.5.3 Recent developments
    - 16.1.5.3.1 Product launches
    - 16.1.5.3.2 Deals
    - 16.1.5.3.3 Expansions
    - 16.1.5.3.4 Other developments
  - 16.1.5.4 MnM view
    - 16.1.5.4.1 Key strengths/Right to win
    - 16.1.5.4.2 Strategic choices
    - 16.1.5.4.3 Weaknesses/Competitive threats
- 16.1.6 DANAHER CORPORATION
  - 16.1.6.1 Business overview
  - 16.1.6.2 Products offered
  - 16.1.6.3 Recent developments
    - 16.1.6.3.1 Product launches
    - 16.1.6.3.2 Deals
    - 16.1.6.3.3 Expansions
  - 16.1.6.4 MnM view
    - 16.1.6.4.1 Key strengths/Right to win
    - 16.1.6.4.2 Strategic choices
    - 16.1.6.4.3 Weaknesses/Competitive threats
- 16.1.7 F. HOFFMANN-LA ROCHE LTD
  - 16.1.7.1 Business overview
  - 16.1.7.2 Products offered
  - 16.1.7.3 Recent developments
    - 16.1.7.3.1 Product launches
    - 16.1.7.3.2 Deals
    - 16.1.7.3.3 Other developments
- 16.1.8 BRUKER
  - 16.1.8.1 Business overview
  - 16.1.8.2 Products offered
  - 16.1.8.3 Recent developments
    - 16.1.8.3.1 Product launches
    - 16.1.8.3.2 Deals
    - 16.1.8.3.3 Expansions
- 16.1.9 QIAGEN
  - 16.1.9.1 Business overview
  - 16.1.9.2 Products offered
  - 16.1.9.3 Recent developments
    - 16.1.9.3.1 Product launches
    - 16.1.9.3.2 Deals
    - 16.1.9.3.3 Expansions
- 16.1.10 BIO-RAD LABORATORIES, INC.
  - 16.1.10.1 Business overview
  - 16.1.10.2 Products offered
  - 16.1.10.3 Recent developments
    - 16.1.10.3.1 Product launches
    - 16.1.10.3.2 Deals
- 16.1.11 TECAN TRADING AG
  - 16.1.11.1 Business overview
  - 16.1.11.2 Products offered
- 16.1.12 TAKARA BIO INC.
  - 16.1.12.1 Business overview
  - 16.1.12.2 Products offered
  - 16.1.12.3 Recent developments
    - 16.1.12.3.1 Product launches
- 16.1.13 CORNING INCORPORATED
  - 16.1.13.1 Business overview
  - 16.1.13.2 Products offered
- 16.1.14 HAMILTON COMPANY
  - 16.1.14.1 Business overview
  - 16.1.14.2 Products offered
  - 16.1.14.3 Recent developments
    - 16.1.14.3.1 Product launches
    - 16.1.14.3.2 Deals
- 16.1.15 PACBIO
  - 16.1.15.1 Business overview
  - 16.1.15.2 Products offered
  - 16.1.15.3 Recent developments
    - 16.1.15.3.1 Product launches
    - 16.1.15.3.2 Expansions
- 16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC
  - 16.1.16.1 Business overview
  - 16.1.16.2 Products offered
  - 16.1.16.3 Recent developments
    - 16.1.16.3.1 Product launches
    - 16.1.16.3.2 Deals
- 16.1.17 PROMEGA CORPORATION
  - 16.1.17.1 Business overview
  - 16.1.17.2 Products offered
- 16.1.18 WATERS CORPORATION
  - 16.1.18.1 Business overview
  - 16.1.18.2 Products offered
  - 16.1.18.3 Recent developments
    - 16.1.18.3.1 Product launches
    - 16.1.18.3.2 Deals
- 16.1.19 SARTORIUS AG
  - 16.1.19.1 Business overview
  - 16.1.19.2 Products offered
  - 16.1.19.3 Recent developments
    - 16.1.19.3.1 Deals
- 16.1.20 BD
  - 16.1.20.1 Business overview
  - 16.1.20.2 Products offered
  - 16.1.20.3 Recent developments
    - 16.1.20.3.1 Product launches
    - 16.1.20.3.2 Deals
- 16.1.21 EPPENDORF SE
  - 16.1.21.1 Business overview
  - 16.1.21.2 Products offered
  - 16.1.21.3 Recent developments
    - 16.1.21.3.1 Deals
- 16.1.22 SHIMADZU CORPORATION
  - 16.1.22.1 Business overview
  - 16.1.22.2 Business overview
  - 16.1.22.3 Products offered
- 16.1.23 AURORA BIOMED INC.
  - 16.1.23.1 Business overview
  - 16.1.23.2 Products offered
- 16.1.24 STANDARD BIOTOOLS
  - 16.1.24.1 Business overview
  - 16.1.24.2 Products offered
- 16.1.25 JEOL LTD.
  - 16.1.25.1 Business overview
  - 16.1.25.2 Products offered
- 16.1.26 GILSON INCORPORATED
  - 16.1.26.1 Business overview
  - 16.1.26.2 Products offered
- 16.1.27 BIOMERIEUX
  - 16.1.27.1 Business overview
  - 16.1.27.2 Products offered
- 16.1.28 GREINER AG
  - 16.1.28.1 Business overview
  - 16.1.28.2 Products offered
- 16.1.29 BGI GROUP
  - 16.1.29.1 Business overview
  - 16.1.29.2 Products offered
- 16.1.30 PORVAIR
  - 16.1.30.1 Business overview
  - 16.1.30.2 Products offered
16.2 OTHER PLAYERS
- 16.2.1 POLARIS GENOMICS
- 16.2.2 BICO
- 16.2.3 CREATIVE BIOARRAY
- 16.2.4 SPHERE BIO
- 16.2.5 GENSCRIPT
- 16.2.6 SCHRODINGER, INC.
- 16.2.7 LECO CORPORATION
- 16.2.8 TRANSGEN BIOTECH CO., LTD
- 16.2.9 BMG LABTECH
- 16.2.10 NANOTEMPER TECHNOLOGIES
- 16.2.11 MGI TECH CO., LTD.
- 16.2.12 ARACELI BIOSCIENCES
- 16.2.13 ANALYTIK JENA GMBH+CO. KG
- 16.2.14 BIOSOLVEIT GMBH
- 16.2.15 EVOSEP

17 RESEARCH METHODOLOGY

17.1 RESEARCH DATA
- 17.1.1 SECONDARY DATA
  - 17.1.1.1 Key data from secondary sources
- 17.1.2 PRIMARY DATA
  - 17.1.2.1 Key data from primary sources
  - 17.1.2.2 Key primary participants
  - 17.1.2.3 Breakdown of primary interviews
  - 17.1.2.4 Key industry insights
17.2 MARKET SIZE ESTIMATION
- 17.2.1 BOTTOM-UP APPROACH
- 17.2.2 TOP-DOWN APPROACH
- 17.2.3 BASE NUMBER CALCULATION
17.3 GROWTH FORECAST MODEL
17.4 DATA TRIANGULATION
17.5 FACTOR ANALYSIS
17.6 RESEARCH ASSUMPTIONS
17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

18 APPENDIX

18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS

簡介目錄圖表

List of Tables

TABLE 1 DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES
TABLE 4 DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD MILLION)
TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022-2024
TABLE 8 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022-2024 (USD MILLION)
TABLE 9 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2022-2024 (USD MILLION)
TABLE 10 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020-2024 (USD THOUSAND)
TABLE 11 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020-2024 (USD THOUSAND)
TABLE 12 IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020-2024 (USD THOUSAND)
TABLE 13 EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020-2024 (USD THOUSAND)
TABLE 14 DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 15 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 16 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES
TABLE 17 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 18 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
TABLE 19 LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023-2025
TABLE 20 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET
TABLE 21 CLIENT'S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS
TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 28 KEY BUYING CRITERIA, BY END USER
TABLE 29 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 30 DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
TABLE 31 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 32 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 34 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 35 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
TABLE 36 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 37 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
TABLE 38 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 39 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 41 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 42 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
TABLE 43 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 44 DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
TABLE 45 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 46 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 48 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 49 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
TABLE 50 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 51 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 52 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 53 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 54 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 55 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 56 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 57 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 58 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 59 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 60 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023-2030 (USD MILLION)
TABLE 61 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 62 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 63 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 64 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 65 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023-2030 (USD MILLION)
TABLE 66 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 67 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023-2030 (USD MILLION)
TABLE 68 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 69 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 70 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE- BASED HTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 71 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 72 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023-2030 (USD MILLION)
TABLE 73 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 74 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023-2030 (USD MILLION)
TABLE 75 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 76 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 77 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 78 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 79 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023-2030 (USD MILLION)
TABLE 80 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 81 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 82 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 83 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 84 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 85 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 86 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 87 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 88 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
TABLE 89 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 90 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 92 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 93 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
TABLE 94 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 95 DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
TABLE 96 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 97 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 98 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 99 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 100 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
TABLE 101 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 102 DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 103 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 104 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 106 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 107 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 108 DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
TABLE 109 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 110 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 111 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 112 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 113 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
TABLE 114 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 115 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
TABLE 116 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 117 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 118 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 119 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 120 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
TABLE 121 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 122 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
TABLE 123 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 124 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 125 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 126 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 127 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
TABLE 128 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 129 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 130 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 131 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 132 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 133 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 134 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 135 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 136 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 137 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 138 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 139 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 140 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 141 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 142 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 143 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 144 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 145 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 146 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 147 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 148 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 149 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 150 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 151 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 152 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 153 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 154 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 155 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 156 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 157 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 158 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 159 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 160 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 161 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 162 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 163 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 164 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 165 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 166 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 167 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 169 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 170 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 171 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 172 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 173 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 174 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 175 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 176 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 177 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 178 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 179 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 180 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 181 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 182 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 183 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 184 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 185 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 186 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 187 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 188 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 189 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 190 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 191 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 192 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 193 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 194 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 195 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 196 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 197 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 198 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 199 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 200 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 201 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 202 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 203 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 204 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 205 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 206 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 207 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 208 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 209 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 210 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 211 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 212 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 213 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 214 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 215 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2030 (USD MILLION)
TABLE 216 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 217 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 218 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 219 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 220 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2030 (USD MILLION)
TABLE 221 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 222 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 223 DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 224 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 225 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 226 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 227 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 228 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 229 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 230 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 231 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 232 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 233 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 234 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 235 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 236 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 237 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023-2030 (USD MILLION)
TABLE 238 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 239 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 240 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 241 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 242 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023-2030 (USD MILLION)
TABLE 243 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 244 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 245 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 246 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 247 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 248 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 249 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 250 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 251 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 252 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 253 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 254 US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 255 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 256 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 257 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 258 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 259 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 260 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 261 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 262 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 263 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 264 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 265 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 266 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 267 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 268 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 269 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 270 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 271 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 272 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 273 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 274 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 275 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 276 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 277 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 278 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 279 UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 280 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 281 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 282 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 283 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 284 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 285 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 286 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 287 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 288 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 289 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 290 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 291 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 292 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 293 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 294 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 295 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 296 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 297 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 298 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 299 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 300 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 301 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 302 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 303 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 304 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 305 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 306 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 307 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 308 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 309 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 310 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 311 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 312 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 313 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 314 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 315 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 316 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 317 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 318 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 319 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 320 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 321 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 322 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 323 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 324 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 325 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 326 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 327 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 328 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 329 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 330 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 331 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 332 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 333 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 334 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 335 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 336 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 337 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 338 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 339 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 340 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 341 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 342 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 343 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 344 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 345 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 346 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 347 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 348 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 349 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 350 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 351 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 352 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 353 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 354 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 355 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 356 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 357 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 358 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 359 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 360 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 361 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 362 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 363 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 364 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 365 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 366 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 367 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 368 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 369 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 370 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 371 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 372 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 373 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 374 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 375 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 376 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 377 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 378 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 379 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 380 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 381 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 382 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 383 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 384 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 385 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 386 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 387 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 388 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 389 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 390 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 391 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 392 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 393 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 394 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 395 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 396 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 397 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 398 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 399 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 400 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 401 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 402 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 403 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 404 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 405 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 406 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 407 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 408 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 409 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 410 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 411 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 412 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 413 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
TABLE 414 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 415 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 416 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 417 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 418 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 419 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2022-NOVEMBER 2025
TABLE 420 DRUG DISCOVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
TABLE 421 DRUG DISCOVERY TECHNOLOGIES MARKET: REGION FOOTPRINT
TABLE 422 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
TABLE 423 DRUG DISCOVERY TECHNOLOGIES MARKET: TECHNOLOGY FOOTPRINT
TABLE 424 DRUG DISCOVERY TECHNOLOGIES MARKET: PROCESS FOOTPRINT
TABLE 425 DRUG DISCOVERY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 426 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 427 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 428 DRUG DISCOVERY TECHNOLOGIES MARKET: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 429 DRUG DISCOVERY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 430 DRUG DISCOVERY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2022-NOVEMBER 2025
TABLE 431 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 432 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 434 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 435 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 436 MERCK KGAA: COMPANY OVERVIEW
TABLE 437 MERCK KGAA: PRODUCTS OFFERED
TABLE 438 MERCK KGAA: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 439 MERCK KGAA: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 440 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 441 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 442 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 443 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 444 REVVITY: COMPANY OVERVIEW
TABLE 445 REVVITY: PRODUCTS OFFERED
TABLE 446 REVVITY: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 447 REVVITY: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 448 REVVITY: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 449 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 450 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 451 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 452 ILLUMINA, INC.: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 453 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 454 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022-NOVEMBER 2025
TABLE 455 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 456 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 457 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 458 DANAHER CORPORATION: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 459 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 460 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 461 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 462 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 463 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 464 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2022-NOVEMBER 2025
TABLE 465 BRUKER: COMPANY OVERVIEW
TABLE 466 BRUKER: PRODUCTS OFFERED
TABLE 467 BRUKER: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 468 BRUKER: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 469 BRUKER: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 470 QIAGEN: COMPANY OVERVIEW
TABLE 471 QIAGEN: PRODUCTS OFFERED
TABLE 472 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 473 QIAGEN: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 474 QIAGEN: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 475 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 476 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 477 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 478 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 479 TECAN TRADING AG: COMPANY OVERVIEW
TABLE 480 TECAN TRADING AG: PRODUCTS OFFERED
TABLE 481 TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 482 TAKARA BIO INC.: PRODUCTS OFFERED
TABLE 483 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 484 CORNING INCORPORATED: COMPANY OVERVIEW
TABLE 485 CORNING INCORPORATED: PRODUCTS OFFERED
TABLE 486 HAMILTON COMPANY: COMPANY OVERVIEW
TABLE 487 HAMILTON COMPANY: PRODUCTS OFFERED
TABLE 488 HAMILTON COMPANY: PRODUCT LAUNCHES
TABLE 489 HAMILTON COMPANY: DEALS
TABLE 490 PACBIO: COMPANY OVERVIEW
TABLE 491 PACBIO: PRODUCTS OFFERED
TABLE 492 PACBIO: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 493 PACBIO: EXPANSIONS, JANUARY 2022-NOVEMBER 2025
TABLE 494 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 495 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED
TABLE 496 OXFORD NANOPORE TECHNOLOGIES PLC.: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 497 OXFORD NANOPORE TECHNOLOGIES PLC.: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 498 PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 499 PROMEGA CORPORATION: PRODUCTS OFFERED
TABLE 500 WATERS CORPORATION: COMPANY OVERVIEW
TABLE 501 WATERS CORPORATION: PRODUCTS OFFERED
TABLE 502 WATERS CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 503 WATERS CORPORATION: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 504 SARTORIUS AG: COMPANY OVERVIEW
TABLE 505 SARTORIUS AG: PRODUCTS OFFERED
TABLE 506 SARTORIUS AG: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 507 BD: COMPANY OVERVIEW
TABLE 508 BD: PRODUCTS OFFERED
TABLE 509 BD: PRODUCT LAUNCHES, JANUARY 2022-NOVEMBER 2025
TABLE 510 BD: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 511 EPPENDORF SE: COMPANY OVERVIEW
TABLE 512 EPPENDORF SE: PRODUCTS OFFERED
TABLE 513 EPPENDORF SE: DEALS, JANUARY 2022-NOVEMBER 2025
TABLE 514 SHIMADZU CORPORATION: COMPANY OVERVIEW
TABLE 515 SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 516 AURORA BIOMED INC.: COMPANY OVERVIEW
TABLE 517 AURORA BIOMED INC.: PRODUCTS OFFERED
TABLE 518 STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 519 STANDARD BIOTOOLS: PRODUCTS OFFERED
TABLE 520 JEOL LTD.: COMPANY OVERVIEW
TABLE 521 JEOL LTD.: PRODUCTS OFFERED
TABLE 522 GILSON INCORPORATED: COMPANY OVERVIEW
TABLE 523 GILSON INCORPORATED: PRODUCTS OFFERED
TABLE 524 BIOMERIEUX: COMPANY OVERVIEW
TABLE 525 BIOMERIEUX: PRODUCTS OFFERED
TABLE 526 GREINER AG: COMPANY OVERVIEW
TABLE 527 GREINER AG: PRODUCTS OFFERED
TABLE 528 BGI GROUP: COMPANY OVERVIEW
TABLE 529 BGI GROUP: PRODUCTS OFFERED
TABLE 530 PORVAIR: COMPANY OVERVIEW
TABLE 531 PORVAIR: PRODUCTS OFFERED
TABLE 532 POLARIS GENOMICS: COMPANY OVERVIEW
TABLE 533 BICO: COMPANY OVERVIEW
TABLE 534 CREATIVE BIOARRAY: COMPANY OVERVIEW
TABLE 535 SPHERE BIO: COMPANY OVERVIEW
TABLE 536 GENSCRIPT: COMPANY OVERVIEW
TABLE 537 SCHRODINGER, INC.: COMPANY OVERVIEW
TABLE 538 LECO CORPORATION: COMPANY OVERVIEW
TABLE 539 TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW
TABLE 540 BMG LABTECH: COMPANY OVERVIEW
TABLE 541 NANOTEMPER TECHNOLOGIES: COMPANY OVERVIEW
TABLE 542 MGI TECH CO., LTD.: COMPANY OVERVIEW
TABLE 543 ARACELI BIOSCIENCES: COMPANY OVERVIEW
TABLE 544 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
TABLE 545 BIOSOLVEIT GMBH: COMPANY OVERVIEW
TABLE 546 EVOSEP: COMPANY OVERVIEW
TABLE 547 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
TABLE 548 RISK ASSESSMENT

List of Figures

FIGURE 1 DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, 2023-2030
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2022-2025
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF DRUG DISCOVERY TECHNOLOGIES MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2025-2030
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG DISCOVERY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 REAGENTS & CONSUMABLES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024
FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN DRUG DISCOVERY TECHNOLOGIES MARKET DURING FORECAST PERIOD
FIGURE 11 REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 DRUG DISCOVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 14 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECASTS UNTIL 2030
FIGURE 15 DRUG DISCOVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 DRUG DISCOVERY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)
FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2024 (USD MILLION)
FIGURE 21 DRUG DISCOVERY TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 22 DRUG DISCOVERY TECHNOLOGIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2025 (USD MILLION)
FIGURE 23 PATENT APPLICATIONS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2014-DECEMBER 2024
FIGURE 24 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET
FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 26 KEY BUYING CRITERIA, BY END USER
FIGURE 27 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 31 DRUG DISCOVERY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARISON
FIGURE 32 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 33 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT
FIGURE 34 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 35 EV/EBITDA OF KEY VENDORS
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2024)
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 43 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
FIGURE 44 BRUKER: COMPANY SNAPSHOT (2024)
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2024)
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 47 TECAN TRADING AG: COMPANY SNAPSHOT (2024)
FIGURE 48 TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT (2024)
FIGURE 50 PACBIO: COMPANY SNAPSHOT (2024)
FIGURE 51 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
FIGURE 52 WATERS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 53 SARTORIUS AG: COMPANY SNAPSHOT (2024)
FIGURE 54 BD: COMPANY SNAPSHOT (2024)
FIGURE 55 EPPENDORF SE: COMPANY SNAPSHOT (2024)
FIGURE 56 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 57 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024)
FIGURE 58 JEOL LTD.: COMPANY SNAPSHOT
FIGURE 59 BIOMERIEUX: COMPANY SNAPSHOT (2024)
FIGURE 60 GREINER AG: COMPANY SNAPSHOT (2024)
FIGURE 61 PORVAIR: COMPANY SNAPSHOT (2024)
FIGURE 62 DRUG DISCOVERY TECHNOLOGIES MARKET: RESEARCH DESIGN
FIGURE 63 DRUG DISCOVERY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 64 DRUG DISCOVERY TECHNOLOGIES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 65 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024)
FIGURE 66 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024)
FIGURE 67 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 68 DRUG DISCOVERY TECHNOLOGIES BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 69 DRUG DISCOVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS
FIGURE 70 DRUG DISCOVERY TECHNOLOGIES MARKET: DATA TRIANGULATION

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球無細胞蛋白合成（CFPS）市場（至2030年）依產品類別（細胞萃取系統、試劑盒、設備和服務）、工作流程、方法和應用分類

藥物研發技術市場（按藥物類型、檢測技術、技術平台、應用和最終用戶分類）—2025-2032 年全球預測

藥物研發技術市場報告：2031 年趨勢、預測與競爭分析

藥物發現技術

FAQ

全球藥物發現技術市場（按產品、技術、製程和治療領域分類）－預測至2030年

Drug Discovery Technologies Market by Product, Technology, Process, Therapeutic Area - Global Forecast to 2030

目錄

第1章 引言

第2章執行摘要

第3章 主要發現

第4章 市場概覽

第5章 產業趨勢

第6章：技術進步、人工智慧影響、專利、創新與未來應用

第7章永續性與監管環境

第8章：顧客狀況與購買行為

第9章 藥物發現技術市場（依產品分類）

第10章 依技術分類的藥物發現技術市場

第11章 按流程分類的藥物發現技術市場

第12章 按治療領域分類的藥物發現技術市場

第13章 依最終用戶分類的藥物發現技術市場

第14章 區域藥物發現技術市場

第15章 競爭格局

第16章：公司簡介

第17章調查方法

第18章附錄

The primary interviews conducted for this report can be categorized as follows:

The report provides insights into the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 EXECUTIVE SUMMARY

3 PREMIUM INSIGHTS

4 MARKET OVERVIEW

5 INDUSTRY TRENDS

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR

9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT

10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY

11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS

12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA

13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER

14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION

15 COMPETITIVE LANDSCAPE

16 COMPANY PROFILES

17 RESEARCH METHODOLOGY

18 APPENDIX

List of Tables

List of Figures

第1章引言

第3章主要發現

第4章市場概覽

第5章產業趨勢

第9章藥物發現技術市場（依產品分類）

第10章依技術分類的藥物發現技術市場

第11章按流程分類的藥物發現技術市場

第12章按治療領域分類的藥物發現技術市場

第13章依最終用戶分類的藥物發現技術市場

第14章區域藥物發現技術市場

第15章競爭格局